This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2B3-201

BBB Therapeutics B.V.

Drug Names(s): Glutathione PEGylated Liposomal Methylprednisolone

Description: 2B3-201, a glutathione PEGylated liposomal methylprednisolone, acts on neuroinflammation through the Company's proprietary G-Technology delivery system.

Deal Structure: In September 2014, to-BBB announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V.

2B3-201 News

Scrip Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

Scrip Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Scrip Pipeline Watch: Phase III Progress With Roche's Baloxavir, Pfizer's Tanezumab And Takeda's Vedolizumab

Scrip Pipeline Watch – Updates From EULAR, EHA and ECNP

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug